1. Home
  2. RPRX vs EQH Comparison

RPRX vs EQH Comparison

Compare RPRX & EQH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RPRX
  • EQH
  • Stock Information
  • Founded
  • RPRX 1996
  • EQH 1859
  • Country
  • RPRX United States
  • EQH United States
  • Employees
  • RPRX N/A
  • EQH N/A
  • Industry
  • RPRX Biotechnology: Pharmaceutical Preparations
  • EQH Specialty Insurers
  • Sector
  • RPRX Health Care
  • EQH Finance
  • Exchange
  • RPRX Nasdaq
  • EQH Nasdaq
  • Market Cap
  • RPRX 16.2B
  • EQH 16.2B
  • IPO Year
  • RPRX 2020
  • EQH N/A
  • Fundamental
  • Price
  • RPRX $40.42
  • EQH $45.22
  • Analyst Decision
  • RPRX Strong Buy
  • EQH Buy
  • Analyst Count
  • RPRX 3
  • EQH 11
  • Target Price
  • RPRX $46.00
  • EQH $64.45
  • AVG Volume (30 Days)
  • RPRX 2.8M
  • EQH 2.7M
  • Earning Date
  • RPRX 11-05-2025
  • EQH 11-04-2025
  • Dividend Yield
  • RPRX 2.18%
  • EQH 2.21%
  • EPS Growth
  • RPRX N/A
  • EQH N/A
  • EPS
  • RPRX 1.77
  • EQH N/A
  • Revenue
  • RPRX $2,349,553,000.00
  • EQH $12,337,000,000.00
  • Revenue This Year
  • RPRX $36.16
  • EQH $17.79
  • Revenue Next Year
  • RPRX $2.04
  • EQH $3.00
  • P/E Ratio
  • RPRX $22.85
  • EQH N/A
  • Revenue Growth
  • RPRX 3.69
  • EQH 17.15
  • 52 Week Low
  • RPRX $24.05
  • EQH $41.39
  • 52 Week High
  • RPRX $41.00
  • EQH $56.61
  • Technical
  • Relative Strength Index (RSI)
  • RPRX 74.39
  • EQH 31.57
  • Support Level
  • RPRX $35.92
  • EQH $47.56
  • Resistance Level
  • RPRX $37.40
  • EQH $49.57
  • Average True Range (ATR)
  • RPRX 1.09
  • EQH 1.16
  • MACD
  • RPRX 0.26
  • EQH -0.02
  • Stochastic Oscillator
  • RPRX 91.94
  • EQH 7.73

About RPRX Royalty Pharma plc

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

About EQH Equitable Holdings Inc.

Equitable Holdings Inc is a financial services company in the U.S. The company provides variable annuities, tax-deferred investment and retirement plans, employee benefits, and protection solutions for individuals, families, and small businesses. Its business segments include Individual Retirement, Group Retirement, Asset Management, Protection Solutions, Wealth Management, and Legacy. It generates the majority of its revenue from the Asset Management segment which provides diversified investment management and related solutions globally to a broad range of clients through three main client channels - Institutional, Retail, and Private Wealth.

Share on Social Networks: